Novo Nordisk A/S (NONOF)
| Market Cap | 261.06B |
| Revenue (ttm) | 49.11B |
| Net Income (ttm) | 17.49B |
| Shares Out | n/a |
| EPS (ttm) | 3.93 |
| PE Ratio | 14.93 |
| Forward PE | 16.26 |
| Dividend | 1.66 (2.75%) |
| Ex-Dividend Date | Mar 28, 2025 |
| Volume | 1,283 |
| Average Volume | 386,769 |
| Open | 60.52 |
| Previous Close | 61.00 |
| Day's Range | 59.00 - 60.52 |
| 52-Week Range | 45.00 - 122.35 |
| Beta | 0.33 |
| RSI | 54.71 |
| Earnings Date | Nov 5, 2025 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.
Financial numbers in DKK Financial StatementsNews
Novo Nordisk Bulks Up Its Obesity-Tied Portfolio With $4.7 Billion Buyout
Novo Nordisk said Thursday it will pay $4.7 billion up front to acquire Akero Therapeutics for its experimental liver disease treatment.
Akero Therapeutics (AKRO) to be Acquired by Novo Nordisk for $5.2 Billion
Akero Therapeutics (AKRO) to be Acquired by Novo Nordisk for $5.2 Billion
Novo Nordisk (NVO) to Acquire Akero Therapeutics in $5.2B Deal
Novo Nordisk (NVO) to Acquire Akero Therapeutics in $5.2B Deal
Novo Nordisk (NVO) Announces Acquisition of Akero Therapeutics for $5.2 Billion
Novo Nordisk (NVO) Announces Acquisition of Akero Therapeutics for $5.2 Billion
Akero Therapeutics Stock Soars on Novo Nordisk Deal.
Novo said it would buy Akero for $54 a share in cash and an additional $6 if it gets U.S. approval of Efruxifermin - it's treatment for fatty liver disease.
Novo Nordisk is paying up to $5.2 billion for a San Francisco biotech working on liver disease
Novo Nordisk, the Danish drugmaker behind Ozempic and other weight-loss drugs, said it’s paying up to $5.2 billion to buy Akero Therapeutics, a biotech with a drug in a late-stage trial to treat a fat...
Novo Nordisk To Buy Akero Therapeutics for $4.7 Billion
Novo said the acquisition of would contribute to its strategy to develop medicines for people living with diabetes, obesity and their associated comorbidities.
Novo Nordisk To Acquire Akero Therapeutics; Akero Shareholders To Receive $54/Shr, CVR Of $6/Shr
(RTTNews) - Novo Nordisk has entered into a definitive agreement to acquire Akero Therapeutics, Inc., a publicly held clinicalstage company developing treatments for patients with serious metabolic di...
Novo Nordisk buys Akero Therapeutics in the US
Danish drugmaker Novo Nordisk said on Thursday it had agreed to buy United States based Akero Therapeutics, a clinical-stage company developing innovative treatments for patients with serious metaboli...
Akero Therapeutics to be acquired by Novo Nordisk for up to $5.2B
Novo Nordisk to acquire Akero Therapeutics and its promising phase 3 FGF21 analogue to expand MASH portfolio
Bagsværd, Denmark, 9 October, 2025 – Novo Nordisk today announced that it has entered into a definitive agreement to acquire Akero Therapeutics, Inc. (Akero), a publicly held clinical-stage company de...
Novo Nordisk: The Lack Of Pricing Power Is A Problem
Final Trade: FCX, NOVO, DE, ZETA
The final trades of the day with the Fast Money traders.
Carolina Wealth Makes a Big $6 Million Bet on Novo Nordisk (NYSE: NVO)
Key PointsCarolina Wealth Advisors, LLC added 102,629 shares of Novo Nordisk A/S, an estimated $6.01 million trade based on the average price for Q3 2025.
Novo Nordisk Cuts U.S. Production Jobs Amid Global Restructuring
Novo Nordisk Cuts U.S. Production Jobs Amid Global Restructuring
Wegovy, Ozempic Maker Novo Nordisk Cuts Staff At Key US Production Sites
Novo Nordisk A/S (NYSE: NVO) has reportedly laid off dozens of employees at its largest U.S. manufacturing site in North Carolina, part of a global restructuring effort under new CEO Mike Doustdar . ...
Novo Nordisk (NVO) Fails to Stop Medicare Drug Price Talks
Novo Nordisk (NVO) Fails to Stop Medicare Drug Price Talks
Novo Nordisk’s appeal to halt Medicare price negotiations rejected
Novo Nordisk: A Profitable Investment In The Long Term
Novo Nordisk (NVO) Reduces Workforce at Key US Manufacturing Site
Novo Nordisk (NVO) Reduces Workforce at Key US Manufacturing Site
Novo Nordisk Cuts Jobs At Key U.S. Drug Plant(edit)
Novo Nordisk Cuts Jobs At Key U.S. Drug Plant(edit)
Wall Street Breakfast Podcast: Deals Don't Wait 'Til November
Amazon (AMZN) launches Prime Big Deal Days, kicking off early holiday shopping with exclusive offers and increased competition from Target and Walmart. Novo Nordisk (NVO) cuts dozens of production job...
Novo Nordisk: Oral Wegovy Nears FDA Decision As GLP-1 Momentum Builds
Novo Nordisk (NVO) Reduces Workforce at Key U.S. Manufacturing Site
Novo Nordisk (NVO) Reduces Workforce at Key U.S. Manufacturing Site